A new treatment discovered to cut the possibility of death from Covid by almost 80 per cent has been approved in the UK.
Xevudy (Sotrovimab), has today been officially accepted by the Medicines and Healthcare products Regulatory Agency (MHRA) after it was discovered to be safe and effective.
The antibody treatment is to the greatest extent effective at the early stages of corona virus illness, and has been given official permission for use by people most at risk of serious illness.
In a declaration the agency said that studies discovered it can reduce the risk of stop infections that stands in need of admission to hospital for treatment or death by 79 per cent.
“In a clinical trial, a single dose of the monoclonal antibody was found to reduce the risk of hospitalization and death by 79% in high-risk adults with symptomatic COVID-19 infection.
“Based on the clinical trial data, sotrovimab is most effective when taken during the early stages of infection and so the MHRA recommends its use as soon as possible and within five days of symptom onset.”
Sotrovimab, developed by pharmaceutical firms GSK and Vir Biotechnology, works by fastening to the spike protein on the outside of the Covid-19 virus.
This stops the virus from joining to and entering human cells, in order to make it impossible to replicate in the body.
It has been approved for people with Covid who have not less than one danger factor which might cause them to develop serious illness – like age, obesity, heart disease and diabetes.
Dr June Raine MHRA, chief executive said:
“I am pleased to say that we now have another safe and effective COVID-19 treatment, Xevudy (sotrovimab), for those at risk of developing severe illness.
“This is yet another therapeutic that has been shown to be effective at protecting those most vulnerable to COVID-19, and signals another significant step forward in our fight against this devastating disease.
“With no compromises on quality, safety and effectiveness, the public can trust that the MHRA have conducted a robust and thorough assessment of all the available data.”
Sotrovimab is not planned to be used as a replacement for vaccination against Covid.
The government and the NHS will confirm how this COVID-19 treatment will be moved into position for action to patients at the appropriate time.